In 2012, the market was valued at $2.2 billion.
The global hospital-acquired disease testing market is broken down by types of infection: pneumonia, urinary tract infection, blood stream infection, surgical site infection, methicillin-resistant Staphylococcus aureus and “others.”
Diagnostic products for hospital-acquired UTIs occupy the largest market share, as it has the highest prevalence, morbidity rate and demand for diagnostic solutions, according to the news release. This market segment itself is expected to reach $2.19 billion in 2019, growing at a compound annual growth rate of 18.1 percent.
Major growth drivers for the healthcare-acquired disease testing market include the existence of highly developed healthcare infrastructure, high rate of healthcare guidelines implementation and an increased awareness of disease prevention, according to the news release.
More Articles on the Medical Device Market:
FDA Approves First Implantable Neurostimulator for Sleep Apnea
Ophthalmology Diagnostics Market to Reach $40B by 2019
Global EMR Market Hit $23B in 2013, Will Continue to Rise
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
